Nephrology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer
Cancer Chemotherapy and Pharmacology, 09/30/09

Sunela KL et al. – The combination of pegylated interferon alfa-2a and capecitabine was active and the response rates seen here were in line with phase-II studies on former combinations of non-pegylated interferons.

Methods

In this open label, single institution, non-randomized phase-II first-line study, 26 patients were included
Capecitabine was administered 2,000 mg/m2 daily for 14 days followed by 1 week rest
Pegylated interferon alfa-2a was given once as weekly injections with a fixed dose of 180 ?g

Results

Response rate was 27, with 4% complete responses
Stable disease was achieved in 42%
The median progression-free survival was 7.5 months; the median overall survival was 17 months
Grades 3–4 toxicity was seen in 46% of patients, but in 93% of cycles no serious toxicity was experienced
Dose reductions had to be done, but in 81% of cycles intensity of 70% or more was possible
Quality of life was better in cycle five than in the base line

<< Previous
Viewpoint: Make more money, save U.S. healthcare

Next >>
Risk of Hyperkalemia in Nondiabetic Patients With Chronic Kidney...